Last reviewed · How we verify
NCT04326803
Hepatitis B en Haitian Immigrants in Chile: Molecular Characterization and Determination of Vaccine Response
Phase 4 trial testing Hepatitis B recombinant vaccine in Hepatitis B in 200 participants. Status unknown.
30 June 2022
Quick facts
| Lead sponsor | Pontificia Universidad Catolica de Chile |
|---|---|
| Phase | Phase 4 |
| Status | Status unknown |
| Study type | INTERVENTIONAL |
| Allocation | na |
| Design | single group |
| Masking | none |
| Primary purpose | prevention |
| Enrollment | 200 |
| Start date | 1 June 2020 |
| Primary completion | 30 June 2022 |
| Estimated completion | 30 December 2023 |
Drugs / interventions tested
- Hepatitis B recombinant vaccine — full drug profile →
Conditions studied
- Hepatitis B — all drugs for Hepatitis B →
Sponsor
Pontificia Universidad Catolica de Chile — full company profile →
Who can join
18 and older, any sex, with Hepatitis B. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
International migration to Chile has sharply increased since 2010. Particularly, Haitian migration now totals approximately 200.000 people. Preliminary results show a high prevalence of hepatitis B infection in this population. Approximately 35% of adult Haitian migrants in Chile have been exposed to hepatitis B infection. In this study the investigators aim to study the clinical and molecular characteristics of this infection and also to assess the serological response to an accelerated schedule of hepatitis B vaccination (0, 1 and 2 months).
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT04326803
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hepatitis B
Currently open trials in the same condition.
- NCT04843852 — TLR-9 Adjuvanted Vaccination for Chronic Hepatitis B · Phase 1 · recruiting
- NCT07168356 — A Study to Evaluate Blood Levels of Bepirovirsen in Adult Participants With Severe or Moderate Kidney Disease · Phase 1 · recruiting
- NCT06947356 — Comparison of TAF and TDF in Preventing Mother-to-Child Transmission of HBV in Pregnancies With High Viral Loads · NA · recruiting
- NCT06537414 — A Study of Sequential Therapy With Daplusiran/Tomligisiran (DAP/TOM) Followed by Bepirovirsen in Participants Living Wit · Phase 2 · active not recruiting
- NCT06623071 — Accupower ® HBV Performance Evaluation Quant Kit Bioneer Existation FA 96/384 · recruiting
Other Pontificia Universidad Catolica de Chile trials
Trials by the same sponsor.
- NCT07396129 — Assessing the Efficacy of a High-Dose Lidocaine-Tetracaine Cream for the Treatment of Peripheral Neuropathic Pain · Phase 1, PHASE2 · not yet recruiting
- NCT07510425 — Artificial Intelligence vs. Automated Messaging for Continuous Regional Analgesia Follow-up · NA · not yet recruiting
- NCT07380451 — Modular Intervention for Depression Study · NA · not yet recruiting
- NCT07324499 — Effect of Dexamethasone on Plasma Levels of Bupivacaine and Dexamethasone After a Single-injection Interscalene Nerve Bl · NA · not yet recruiting
- NCT07330947 — Incidence and Risk Factors of Postoperative Chronic Pain in Patients Who Have Undergone Hallux Valgus Surgery · not yet recruiting
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04326803 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Pontificia Universidad Catolica de Chile
- Last refreshed: 31 March 2020
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04326803.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing